Aardvark Therapeutics, Inc. (AARD)

Aardvark Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2024
Period Ending	Dec 31, 2024	Dec 31, 2023
Selling, General & Admin	5.31	2.17
Research & Development	17.36	4.48
Other Operating Expenses	0.12	0.76
Total Operating Expenses	22.79	7.42
Operating Income	-22.79	-7.42
Interest Income	2.41	1.42
Other Non-Operating Income (Expense)	0.22	1.22
Total Non-Operating Income (Expense)	2.63	2.64
Pretax Income	-20.15	-4.78
Net Income	-20.59	-7.21
Net Income to Common	-20.59	-7.21
Shares Outstanding (Basic)	4	4
Shares Outstanding (Diluted)	4	4
Shares Change (YoY)	0.90%	-
EPS (Basic)	-5.15	-1.82
EPS (Diluted)	-5.15	-1.82
Free Cash Flow	-18.2	-5.82
Free Cash Flow Per Share	-4.55	-1.47
EBITDA	-22.77	-7.42
EBIT	-22.79	-7.42

Updated Aug 13, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q